NO20042155L - N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling - Google Patents

N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling

Info

Publication number
NO20042155L
NO20042155L NO20042155A NO20042155A NO20042155L NO 20042155 L NO20042155 L NO 20042155L NO 20042155 A NO20042155 A NO 20042155A NO 20042155 A NO20042155 A NO 20042155A NO 20042155 L NO20042155 L NO 20042155L
Authority
NO
Norway
Prior art keywords
adamantylmethyl
intermediates
derivatives
processes
preparation
Prior art date
Application number
NO20042155A
Other languages
English (en)
Norwegian (no)
Inventor
Lilian Alcaraz
Timothy Johnson
Micheal Stocks
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20042155L publication Critical patent/NO20042155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042155A 2001-11-16 2004-05-25 N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling NO20042155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds
PCT/SE2002/002057 WO2003041707A1 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation

Publications (1)

Publication Number Publication Date
NO20042155L true NO20042155L (no) 2004-08-16

Family

ID=20286020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042155A NO20042155L (no) 2001-11-16 2004-05-25 N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling

Country Status (29)

Country Link
US (1) US7129246B2 (pl)
EP (1) EP1448195B1 (pl)
JP (1) JP4559077B2 (pl)
KR (1) KR20040058290A (pl)
CN (1) CN1585640B (pl)
AR (1) AR037534A1 (pl)
AT (1) ATE344034T1 (pl)
AU (1) AU2002347741B2 (pl)
BR (1) BR0214142A (pl)
CA (1) CA2464863A1 (pl)
CO (1) CO5580747A2 (pl)
DE (1) DE60215851T2 (pl)
DK (1) DK1448195T3 (pl)
ES (1) ES2274110T3 (pl)
HU (1) HUP0402560A3 (pl)
IL (1) IL161693A0 (pl)
IS (1) IS7261A (pl)
MX (1) MXPA04004498A (pl)
MY (1) MY136430A (pl)
NO (1) NO20042155L (pl)
NZ (1) NZ532755A (pl)
PL (1) PL370855A1 (pl)
PT (1) PT1448195E (pl)
RU (1) RU2300525C2 (pl)
SE (1) SE0103836D0 (pl)
TW (1) TW200407297A (pl)
UA (1) UA77978C2 (pl)
WO (1) WO2003041707A1 (pl)
ZA (1) ZA200403682B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
RU2460727C2 (ru) * 2007-03-22 2012-09-10 Астразенека Аб Хинолиновые производные для лечения воспалительных заболеваний
CN103204852A (zh) 2007-04-10 2013-07-17 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
AU2009228649B2 (en) 2008-03-25 2014-05-22 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
MX2014000894A (es) 2011-07-22 2014-02-27 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7.
TWI576347B (zh) 2012-01-20 2017-04-01 艾克泰聯製藥有限公司 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物
KR101576235B1 (ko) 2012-11-30 2015-12-11 한국생명공학연구원 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
JP6282017B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JP6282016B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
CN104163795B (zh) * 2014-08-19 2016-02-03 四川大学 盐酸烟酰美金刚胺溶剂合物、其制备方法和用途
CN104628616B (zh) * 2015-02-12 2016-06-01 佛山市赛维斯医药科技有限公司 含对硝基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628615B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 含卤代苯的n-金刚烷酰胺类化合物、其制备方法及其用途
CN104628617B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 N-金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途
CN104693084B (zh) * 2015-02-12 2016-03-16 佛山市赛维斯医药科技有限公司 含腈基苯基的n-金刚烷酰胺类化合物、其制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) * 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4027035A (en) * 1968-08-27 1977-05-31 Eli Lilly And Company Therapeutic uses of adamantanealkylamine compounds
GB1274652A (en) * 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) * 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
EP0424538A4 (en) * 1989-03-10 1992-07-22 Idemitsu Kosan Company Limited Pyridine derivatives and their salts, and insecticidal/acaricidal agent containing the same as active ingredient
PL181782B1 (pl) 1993-08-10 2001-09-28 Black James Foundation Nowe zwiazki i sposób wytwarzania nowych zwiazków PL
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
TR200102911T2 (tr) 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
DE60215851T2 (de) 2007-05-24
IS7261A (is) 2004-05-13
KR20040058290A (ko) 2004-07-03
RU2300525C2 (ru) 2007-06-10
UA77978C2 (en) 2007-02-15
SE0103836D0 (sv) 2001-11-16
CO5580747A2 (es) 2005-11-30
ATE344034T1 (de) 2006-11-15
DE60215851D1 (de) 2006-12-14
CA2464863A1 (en) 2003-05-22
WO2003041707A1 (en) 2003-05-22
AR037534A1 (es) 2004-11-17
CN1585640A (zh) 2005-02-23
JP2005519028A (ja) 2005-06-30
JP4559077B2 (ja) 2010-10-06
PT1448195E (pt) 2007-02-28
CN1585640B (zh) 2010-10-27
NZ532755A (en) 2005-11-25
DK1448195T3 (da) 2007-02-12
MXPA04004498A (es) 2004-08-11
RU2004112780A (ru) 2005-10-10
MY136430A (en) 2008-10-31
TW200407297A (en) 2004-05-16
IL161693A0 (en) 2004-09-27
AU2002347741B2 (en) 2008-03-13
US7129246B2 (en) 2006-10-31
HK1067048A1 (en) 2005-04-01
HUP0402560A2 (hu) 2005-04-28
ZA200403682B (en) 2005-08-03
PL370855A1 (pl) 2005-05-30
ES2274110T3 (es) 2007-05-16
EP1448195B1 (en) 2006-11-02
HUP0402560A3 (en) 2009-03-02
BR0214142A (pt) 2004-09-14
EP1448195A1 (en) 2004-08-25
US20050010052A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
DK1448195T3 (da) N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
DK1420759T3 (da) Farmaceutiske sammensætninger til behandling af astma
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
DK1368349T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20050830L (no) Acylerte heteroarylkondenserte sykloalkenylaminer og deres anvendelse som farmasoytiske midler
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
IS7051A (is) Lyfjasamsetningar
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
DK1406899T3 (da) Phenylacetamidothiazolderivater, fremgangsmåder til deres fremstilling og deres anvendelse som antitumormidler
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20023643D0 (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
FI20022128A7 (fi) Farmaseuttinen koostumus
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
NO20031643D0 (no) Nye aminotriazolonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20021198L (no) Nye isoindoloindolonforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20035215D0 (no) Tricykliske dihydrokinolinforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20021330L (no) Nye indenoindolonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20043910L (no) Nye aminosyreforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DK1256583T3 (da) Pyrimidin-4-on-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application